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The New Zealand cancer registry was established in 1948, with compulsory registration of cancer cases dating from 
1994. Population-based cancer registration 
makes it possible to monitor trends in survival 
for each type of cancer by age, gender and 
other factors including, in New Zealand (NZ), 
ethnicity. These trends are published regularly 
by the NZ Ministry of Health, the most recent 
covering the period 1994 to 2009.1 
Robust and consistent systems of cancer 
registration also permit international 
comparisons of cancer survival. These 
comparisons can help countries to identify 
problems in their registration systems and 
to benchmark the performance of their 
health systems against similar countries. 
A comparison of cancer survival in Britain 
with that of the rest of Europe found that 
6–7% of the excess deaths among cancer 
patients (the number of deaths in excess of 
the expected or background mortality) would 
have been avoidable if survival in Britain were 
as high as the mean for Europe, and 10.6% if 
it had been as good as that in the European 
countries with highest survival.2 Britain’s 
poor performance in comparisons with other 
developed countries was a driver for the 
investment and policies set out in the 2011 
national cancer strategy.3
Survival estimates for 1999–2007 from 107 
cancer registries in 29 European countries 
collated through the EUROCARE project have 
been published.4 The first CONCORD study 
compared cancer survival for breast, colon, 
rectum and prostate from 101 registries in 
31 countries on five continents.5 Australia 
participated, but not NZ. CONCORD-2 will 
extend these comparisons to 10 common 
cancers with data from more than 250 cancer 
registries in about 60 countries, including NZ. 
To our knowledge, no published studies 
have provided a direct and comprehensive 
comparison of cancer survival in NZ with 
that in Australia. Survival in Australia ranked 
in the top 10 in the CONCORD study for all 
four cancers examined and in both sexes, 
making it a high-performing comparator for 
NZ. We have compared cancer survival in 
NZ and Australia using a similar approach to 
Abdel-Rahman et al.2 to estimate the number 
and proportion of excess deaths that would 
have been avoidable among patients with 
each type of cancer in NZ if survival were 
equivalent to that in Australia.
Literature on the epidemiology of cancer 
survival has established the concepts of 
‘avoidable’ and ‘excess’ cancer deaths used 
in this paper.2,6-11 Formal definitions are 
provided in the methods section, but we 
emphasise that the term ‘avoidable cancer 
deaths’ is used in comparisons of two or 
more populations to indicate the numbers 
of individuals in the population(s) with lower 
relative survival (of cancer) who would have 
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Abstract
Aim: To determine how many Māori and non-Māori deaths might have been avoidable if 
cancer survival in New Zealand were as high as in Australia.
Methods: Age-sex-tumour specific five-year relative survival ratios were calculated for cancer 
patients diagnosed with 27 tumour sites (representing about 92% of all cancers) in 2006–10. 
These were used to estimate the number of Māori, non-Māori and total deaths (and proportion 
of excess deaths) that would have been avoidable within five years of diagnosis had New 
Zealand’s relative survival been equivalent to Australia’s. 
Results: A total of 3,631 cancer deaths (726/year; 13.4% of excess deaths) could have been 
avoidable. Among 25 tumours where ethnic-specific results were estimated, there were 
851 potentially avoidable deaths in Māori (24.9%) and 2,758 in non-Māori (11.8%). Breast, 
bowel, lung and prostate tumours made up 64% of avoidable deaths. Those with the highest 
proportions of avoidable deaths were thyroid (44.7%), prostate (35.5%), breast (30.0%) and 
uterus (23.5%). More than 50% of Māori melanoma, prostate, testis and thyroid cancer deaths 
were avoidable. 
Conclusion: A significant number of cancer deaths could be avoidable if New Zealand achieved 
Australia’s relative survival ratios. The proportion is much higher for Māori than for non-Māori.
Implications: There is considerable scope to improve cancer outcomes in New Zealand.
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survived, had relative survival been as high 
as in the population with the best relative 
survival ratio. The deaths are only truly 
avoidable if the population with the lower 
relative survival could potentially achieve 
the higher relative survival ratio. This issue is 
revisited in the discussion section.
Similarly, confusion may arise with the term 
‘excess’ cancer deaths. In this case the ‘excess’ 
refers to deaths in patients diagnosed with 
cancer that are over and above those that 
would have been expected in the general 
population without cancer. Excess deaths 
can be thought of as the number of deaths in 
patients diagnosed with cancer that can be 
attributed to the cancer within the follow-up 
period (in this case five years).
The other term used extensively in this 
paper is ‘relative survival’. It is widely used 
in cancer epidemiology and refers to the 
ratio of observed survival (e.g. in a group of 
cancer patients) to the survival of the general 
population.12 Deaths in the general population 
are referred to as background mortality. 
Methods
Data sources
Estimates of the five-year cumulative relative 
survival ratio by age and sex for each type 
of cancer for patients diagnosed Australia in 
2006–10 were obtained from online tables 
published by the Australian Institute of Health 
and Welfare.13 These are derived from the 
Australian Cancer Database (ACD), which 
is compiled and maintained by AIHW in 
partnership with the Australasian Association 
of Cancer Registries.14 Each Australian state 
and territory has a separate registry, but these 
have a minimum data set that is submitted 
to the Australian Cancer Database: all states 
have legislation making the reporting of 
cancer mandatory. AIHW performs internal 
linking checks to identify patients who had 
tumours diagnosed in more than one state 
or territory, thus reducing duplication to a 
negligible level. Death records held in the 
National Death Index are routinely linked to 
the ACD. Additional detail on the Australian 
Cancer Database and National Death Index 
are provided in Appendix C of the report.14
The NZ cancer registry provided data for 
patients diagnosed between 2001 and 2007 
and followed up to 31 December 2010. These 
data make it possible to apply the period 
approach to predict five-year relative survival 
for patients diagnosed in 2006–10 by using 
the survival experience of patients who were 
diagnosed in earlier years and who were 
alive at some point during 2006–10. The 
NZ registry performs a number of routine 
measures to maximise the quality of the data. 
Additional details on the content and quality 
of the data are provided on the Ministry of 
Health website (http://www.health.govt.nz).
Both the NZ and Australian registries used the 
tenth revision of the International Statistical 
Classification of Diseases and Related Health 
Problems (ICD-10) for coding the tumour site 
throughout the period covered by this study.
AIHW linked data on deaths from the 
Australian National Mortality Database to the 
Australian Cancer Database to estimate the 
survival time of each cancer patient. All-cause 
mortality rates from the Australian Bureau 
of Statistics were used to derive national life 
tables of background mortality in order to 
estimate expected survival.
Data on deaths in NZ are recorded in the 
National Mortality Collection, equivalent to 
the Australian National Mortality Database. 
Death records registered on or before 31 
December 2010 were linked to the cancer 
registry by their encrypted National Health 
Index number to establish the survival time 
for each patient. Complete period life tables 
for 2000–02, 2005–07 and 2010–12 for Māori 
and non-Māori, produced by Statistics NZ, 
were interpolated using the fraction method 
described by Micheli et al.15 to produce life 
tables for each year from 2001 to 2010. 
Cancers studied
We studied the same 27 malignancies for 
which AIHW has published survival estimates: 
these represented 91.8% of all cancers 
diagnosed in NZ during the period 2006–
2010. The ICD-10 codes used to define each 
cancer type are shown in Table 1.
Selection criteria
The selection criteria used by AIHW were 
followed as closely as possible in selecting the 
NZ patients to be included in the analyses. 
The only difference in exclusion criteria 
between the Australian and NZ data was that 
NZ patients aged 100 or over were excluded 
from the analyses because the life tables 
available for 2006–07 did not extend beyond 
the age of 100, making it difficult to estimate 
expected survival. The effect on survival 
estimates would be negligible, given that 
there were only 18 patients diagnosed at age 
100 years or over in the NZ data (0.1% of all 
those aged 80 and over). Table 2 shows the 
included and excluded population of the NZ 
and Australian groups.
Survival and avoidable deaths
Avoidable cancer deaths were calculated 
in the same manner as Abdel-Rahman et 
al.2 This method partitions the total deaths 
into those that are ‘expected’ given the 
background mortality rate in the population 
and ‘excess’ deaths attributable to the 
cancer.16 For each cancer, the number of 
excess deaths was calculated as: 
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where N is the incident number of cases of cancer, E is the expected survival, 
and R is the five-year relative survival ratio in age group i, sex j and ethnic 
group (Māori or non-Māori) k. 
Relative survival is the ratio of the observed 
cumulative probability of survival in patients 
with tumour who survive a given period 
(in this case five years) and the survival that 
would have been expected during that 
time if the patients were only subject to 
the background mortality in the general 
population group (obtained from life tables). 
Relative survival ratios using the period 
approach17 were available for Australia 
using the Ederer II method,12 as described in 
the Australian cancer survival report.14 We 
followed the same methodology to calculate 
relative survival ratios for NZ. Unlike the 
cohort method, the period method gives 
more up-to-date estimates of cancer survival 
by making use of all survival information up 
to the final point of follow-up.
Data were obtained on all cancer patients 
diagnosed in NZ during 2001–07 and 
followed up until 31 December 2010. Relative 
survival ratios were calculated using the 
period approach to predict five-year relative 
survival in 2006–10 using the strs command 
in Stata. Relative survival was estimated 
separately for Māori and non-Māori.
Period estimates of the Australian five-year 
relative survival ratios for the same period 
(2006–10), again based on patients diagnosed 
from 2001 to 2007, were taken from the 
AIHW publication. Australian relative survival 
estimates were not published for age-sex 
strata with fewer than 20 individuals alive 
at the start of the follow-up year, and these 
strata were excluded from the avoidable 
mortality calculations. 
‘Avoidable’ deaths are estimated as the 
number of excess deaths that would not have 
occurred if five-year relative survival in NZ in 
each age-sex group for each cancer had been 
equivalent to that in Australia for 2006–10:
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Cancer Avoidable cancer deaths in New Zealand
Table 1: Total number of excess deaths and number of deaths that would be avoidable in New Zealand within 5 years of diagnosis, if survival were the same as in Australia: 
selected cancers, adults (15–99 years), Māori and non-Māori, diagnosed during 2006-2010.
Site/type
ICD 10 
Codes
Total malignant 
cancers 2006-10
Excess deaths Avoidable deaths
Māori non-Māori Total Māori non-Māori Total
No. % of excessa No. % of excess No. % of excess
AML See note b 859 53 478 531 2 2.9 3 0.6 4 0.8
Bladder C67 1,726 37 549 586 13 34.3 22 4.0 35 5.9
Bowel C18-C20 13,677 295 4,073 4,368 117 39.6 483 11.9 600 13.7
Brain C71 1,317 69 813 882 11 15.6 39 4.8 50 5.7
Breast C50 13,368 269 1,494 1,763 134 49.8 395 26.4 529 30.0
Cervix C53 806 46 149 195 11 23.4 -13 - -2 -
CLL C91.1 1,001 18 165 183 5 28.6 -31 - -26 -
Gall bladder C23-C24 494 43 297 340 6 13.5 18 6.0 23 6.9
Hodgkin C81 477 1 61 62 -1 - 14 22.9 13 20.5
Kidney C64 2,146 68 540 608 30 43.4 77 14.3 107 17.5
Larynx C32 422 19 125 145 4 21.8 16 12.6 20 13.8
Lipc C00 225 - - 25 - - - - 11 43.8
Liver C22 1,082 178 604 782 21 12.0 37 6.2 59 7.5
Lung C33-C34 8,685 1,338 5,489 6,827 208 15.6 488 8.9 697 10.2
Melanoma C43 13,513 35 1,280 1,315 24 68.7 257 20.1 281 21.4
Mesotheliomac C45 435 - - 344 - - - - 10 3.0
Myeloma C90 1,344 69 575 645 23 33.8 18 3.1 41 6.4
Non-Hodgkins C82-C85 3,604 86 992 1,078 39 44.7 187 18.8 225 20.9
Oesophagus C15 1,343 83 910 993 14 16.3 85 9.4 99 10
Ovary C56 1,365 89 667 756 25 28.5 67 10 92 12.2
Pancreas C25 1,970 168 1,389 1,557 8 4.5 58 4.2 66 4.2
Prostate C61 14,493 124 1,202 1,325 89 71.9 382 31.8 471 35.5
Stomach C16 1,772 246 899 1,144 42 17.2 58 6.5 101 8.8
Testis C62 784 9 11 19 5 52.9 -5 - 0 -
Thyroid C73 1,157 12 65 77 7 62.4 27 41.6 35 44.7
Tongue C01-C02 490 14 146 160 3 19.9 -8 - -5 -
Uterus C54-C55 2,100 46 361 408 12 26.5 84 23.1 96 23.5
TOTAL 90,655 3,417 23,333 27,119 851 24.9 2,758 11.8 3,631 13.4
a: These are calculated from unrounded estimates and therefore may differ from those calculated from the numbers presented in the table.
b: ICD codes C92.0, C92.3-C92.5, C93.0, C94.0, C94.2, C94.4, C94.5
c: Numbers were too small to produce ethnic specific estimates for these tumours.
Abbreviations: AML = Acute myeloid leukaemia  CLL = Chronic lymphocytic leukaemia
Table 2: Summary of data included and excluded from period survival analysis.
Criteria Australia14 New Zealand
Number % Number %
Patients included in analyses 1,929,154 97.9 114,169 96.8
Patients excludeda
 Age at diagnosis not knownb
 Death certificate only
 Invalid age
 Invalid sequence of death and diagnosis datesb
 Zero survival timec
 Multiple primary, same side and sited
42,031
189
30,868
125
27
31,153
-
2.1
0.0
1.6
0.0
0.0
1.6
-
3,670
0
3,012
29
0
1,903
56
3.1
0.0
2.6
0.0
0.0
1.6
0.0
Total cases diagnosede 1,971,185 100.0 117,895 100.0
a:  Some patients met more than one criterion for exclusion.
b:  These may have already been excluded from the New Zealand cancer registry data.
c:  These exclusions are standard practice in survival analysis of cancer registry data and since they constitute just a small percentage of the total records their 
exclusion is unlikely to significantly change the overall results.
d:  Other multiple primaries were included as recommended by Rosso et al32.
e:  For Australia the period is 1982-2007, for New Zealand the period is 2001-2007. Patients not domiciled in the country have already been excluded, as have 
secondary tumours, non-malignant tumours and recurrences from an already registered primary site. 
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where Eijk is the expected survival in NZ in stratum ijk and is the number 
of incident tumours in NZ during 2006–2010. Avoidable deaths were 
calculated separately for Māori and non-Māori, for age and sex, and for 
each tumour type, using the Australian population as the sole comparator. 
Ethnic-specific numbers of avoidable deaths were not presented for the 
tumour groups in which there were fewer than 20 Māori cases in the 
five-year period (lip, mesothelioma and unknown site). Avoidable deaths 
were calculated and presented for the five-year period 2006–2010 and 
also as annual numbers. In addition to presenting absolute numbers of 
avoidable deaths, we present them as percentages of excess deaths for 
each tumour type. 
Ethnicity
Ethnicity was classified as Māori or non-
Māori in accordance with the available life 
tables. In NZ, ethnicity is based on self-
declaration and multiple ethnicities are 
recorded.18 To deal with multiple ethnicities, 
a subject with any ethnicity code of Māori 
was classified as Māori. The way ethnicity 
was assigned in the NZ Cancer Registry 
changed in 2009 with the introduction of 
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an ethnicity algorithm to reduce previously 
documented undercounting of Māori Pacific 
and Asian events.19,20 This algorithm was run 
retrospectively across all registrations back 
to 1989 and so applied to all of the data 
used in this analysis. This algorithm searches 
the National Health Index, the Mortality 
Collection and National Minimum Dataset for 
ethnicity information. The ethnicity recorded 
in the cancer registry dataset was taken as 
definitive. 
Māori and non-Māori life tables rely on 
census and mortality collection data for 
ethnicity classification. Record-linkage studies 
have found reasonably good agreement 
between the two sources.21 Clearly, cancer 
survival analysis relies on multiple sources of 
ethnicity measurement of varying quality and 
accuracy, with census data regarded as the 
gold standard. A recent study suggests that 
the quality of hospital ethnicity data (widely 
used in the cancer registry), has improved 
over time and is now quite high.22
Results
A total of 90,655 NZ patients with one of the 
27 types selected for study were diagnosed 
between 1 January 2006 and 31 December 
2010 (Table 1), among whom 27,119 deaths 
in excess of the number expected from 
background mortality were recorded. Relative 
cancer survival was generally lower in NZ 
than in Australia, and some excess deaths 
would have been avoidable for 23 of the 27 
cancers if survival had been the same in NZ as 
in Australia (24 of 25 for Māori and 21 of 25 for 
non-Māori). 
For cancers with lower five-year survival in 
NZ than in Australia, 3,663 deaths would 
have been avoidable if NZ had experienced 
the same relative survival as Australia (13.5% 
of excess deaths). For cancers with higher 
survival in NZ than Australia, only 33 deaths 
were avoided in NZ (0.1% of excess deaths), 
Table 1. The net effect of these differences in 
five-year relative survival between Australia 
and NZ was 3,631 avoidable deaths among 
cancer patients diagnosed in NZ over the 
five-years 2006–10, or 726 deaths per year 
(13.4% of the excess deaths). It was found that 
a flat increase of 4.6% in NZ survival across all 
tumour groups would be needed to reduce 
the number of avoidable deaths to zero.
Māori made up 851 of the avoidable deaths 
(170 per year), representing 24.9% of all 
excess deaths among Māori. Avoidable 
deaths comprised more than 50% of the 
excess deaths among Māori for melanoma, 
prostate, testis and thyroid. 
Among non-Māori, the 2,758 avoidable 
deaths (552 per year) represented 11.8% of 
the excess deaths. The highest proportion 
was for thyroid cancer (41.6%). More than 
20% of excess deaths would have been 
avoidable for six of the 25 cancers for which 
survival was lower in NZ (thyroid, breast, 
Hodgkin, prostate, uterus and melanoma), 
and more than 10% for a further five tumour 
sites (non-Hodgkin lymphoma, kidney, larynx, 
bowel and ovary).
The proportion of avoidable deaths was 
almost always higher for Māori than non-
Māori. The only malignancy for which the 
proportion of avoidable deaths was lower 
in Māori than non-Māori was Hodgkin 
lymphoma, the least common of the 
malignancies for which separate estimates 
could be made for each ethnicity. 
The proportionate distribution of avoidable 
deaths in Māori and non-Māori cancer 
patients is shown in Figure 1. Seven of the 25 
malignancies with avoidable excess deaths 
in NZ accounted for 77% of all the avoidable 
deaths in Māori and 82% in non-Māori, but 
their relative importance varied somewhat, 
with stomach and lung making up higher 
proportions in Māori and melanoma 
accounting for a higher proportion in non-
Māori. Cancers with the highest proportions 
of avoidable excess deaths for Māori and 
non-Māori were thyroid (39.2.0%), lip (31.7%), 
breast (26.1%) and prostate (25.8%).
Discussion
The application of health needs analysis to 
public health practice, resource allocation, 
prioritisation and service performance 
appraisal is often frustrated by the difficulty 
of determining how much of a given health 
burden is truly avoidable. Benchmarking 
against a high-performing comparator is 
one way to achieve this aim. Australia’s high 
cancer survival compared with other (mainly 
European) countries in the CONCORD study5 
suggests that it may be as good as ‘the best 
of Europe’.
Australia is a significantly wealthier country 
than NZ, with higher levels of per person 
health expenditure (US$3,800 versus 
US$3,042 in 2010),23 and slightly higher life 
expectancy.24 Total health expenditure is 
a relatively crude metric of health system 
investment in the management of cancer, 
but it is correlated with survival,25,26 and so 
it is not surprising that survival in Australia is 
higher than in NZ. The results are consistent 
with those from the CONCORD study, where 
poorer countries tended to have lower cancer 
survival ratios,5 and survival among blacks in 
the US was lower than among whites. 
The estimates of avoidable deaths are 
derived from differences in five-year survival 
after taking into account the differences in 
background mortality by age, sex and over 
time between countries, and, in NZ, between 
Māori and non-Māori. The avoidable deaths 
in NZ may reflect a combination of earlier 
diagnosis, faster access to treatment and 
more effective therapy in Australia. 
Previous international comparisons of 
cancer survival have been criticised on the 
grounds that differences in the quality of 
registration systems may account for some 
of the estimated differences in survival.27 
Survival in NZ could appear lower than in 
Australia if the follow-up of cancer patients 
were more complete in NZ than Australia. This 
is unlikely: both countries have compulsory 
cancer registration and national mortality 
databases of high quality and completeness. 
Further, the survival estimates for NZ were 
derived with specific life tables for each sex 
and ethnicity, while the Australian estimates 
were derived with a single set of life tables for 
each sex, so the estimates of avoidable deaths 
are more likely to be conservative. This is 
because some Māori deaths that would have 
been attributed to cancer (as excess deaths) 
with national life tables are taken (correctly) 
as background mortality and hence the 
Figure 1: Distribution of avoidable deaths by tumour site and ethnicity.
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relative survival in that group increases. If 
separate life tables had been used for Pacific 
ethnicity patients then the non-Māori relative 
survival estimates would have been slightly 
higher, but there would still have been a 
survival deficit between NZ and Australia. 
Using separate life tables for Aboriginal and 
Torres Strait Island Australians (2.3% of the 
population in the 2011 census) would have 
had only a very small effect on the avoidable 
mortality estimates.
For certain sites, lead-time bias and over-
diagnosis may explain some of the observed 
survival differences. For example, variation 
in the use of prostate-specific antigen, and 
in the intensity of investigation following 
an abnormal result, could lead to a higher 
proportion of relatively indolent prostate 
tumours. It is not known whether Australia 
differs from NZ in this respect, but it is 
noteworthy that the age-standardised 
incidence rate of prostate cancer during 
2003–07 was higher in Australia than in 
NZ (120.0 versus 102.6 per 100,000).28,29 
Prostate cancer comprised 25.7% of the 
total avoidable excess deaths among men. 
Excluding prostate cancer reduces the total 
number of avoidable deaths to 3,193, which is 
12.4% of non-prostate excess mortality.
Similarly, more complete or more thorough 
breast screening (e.g. through earlier 
introduction of digital mammography) 
might also introduce lead-time bias, length 
bias or over-diagnosis, which could affect 
survival. One might expect this to produce 
higher incidence rates but incidence rates 
in Australia and NZ during 2003–07 were 
almost identical (89.3 versus 90.6). It is less 
likely that such biases could explain the 
large differences in survival for non-Hodgkin 
lymphoma, where incidence rates in Australia 
and NZ were also similar (13.9 and 14.8).28,29
These findings once again draw attention 
to the unacceptable ethnic disparities in 
cancer survival in NZ, which have been 
noted by others,30 but they also demonstrate 
that the problem is not simply one of 
ethnic disparities. The absolute numbers of 
avoidable deaths were higher for non-Māori 
than Māori. In other words, the survival 
disparities with Australia are far higher for 
Māori, with more than 50% of avoidable 
excess deaths for several cancers, but the 
number of avoidable excess deaths is higher 
among non-Maori, because they represent 
a higher proportion of all cancer patients. It 
was not possible from this work to examine 
the ethnic inequalities in Australian cancer 
survival, but it should be noted that these are 
also unacceptably large.31
The proportion of all excess deaths that 
are potentially avoidable in this study of 27 
tumour types comprising about 92% of all 
cancers gives an indication of the scope for 
improvement in survival in NZ. Although we 
calculated that five-year relative survival in 
NZ would have to have been 4.6% higher for 
all tumour sites to eliminate the avoidable 
mortality compared Australia, the disparities 
in survival are not evenly distributed, and so 
there is greater scope for improvement with 
some tumour types than others (e.g. prostate, 
thyroid, breast and lip).  
For 20 of the 27 malignancies we studied, 
at least 5% of the excess deaths among NZ 
cancer patients were potentially avoidable. 
These sites are heterogeneous in terms of 
organ system, treatment modality and the 
existence of a national screening program. 
This suggests that the causes of the survival 
disparities with Australia may be general 
rather than tumour-specific. However, it may 
require careful and detailed comparative 
research into those specific tumour sites with 
the largest proportions of avoidable deaths in 
order to elucidate these underlying reasons 
for the survival differences. 
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